- Home
- BRNS vs INTS Comparison
BRNS vs INTS Comparison
Compare BRNS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- INTS
- Stock Information
- Founded
- BRNS 2016
- INTS 2012
- Country
- BRNS United Kingdom
- INTS United States
- Employees
- BRNS N/A
- INTS N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- INTS Health Care
- Exchange
- BRNS Nasdaq
- INTS Nasdaq
- Market Cap
- BRNS 28.2M
- INTS 30.8M
- IPO Year
- BRNS 2021
- INTS 2023
- Fundamental
- Price
- BRNS $0.84
- INTS $0.90
- Analyst Decision
- BRNS Strong Buy
- INTS Strong Buy
- Analyst Count
- BRNS 2
- INTS 3
- Target Price
- BRNS $3.00
- INTS $8.50
- AVG Volume (30 Days)
- BRNS 25.3K
- INTS 78.2K
- Earning Date
- BRNS 05-12-2025
- INTS 05-08-2025
- Dividend Yield
- BRNS N/A
- INTS N/A
- EPS Growth
- BRNS N/A
- INTS N/A
- EPS
- BRNS N/A
- INTS N/A
- Revenue
- BRNS $14,969,000.00
- INTS N/A
- Revenue This Year
- BRNS N/A
- INTS N/A
- Revenue Next Year
- BRNS N/A
- INTS N/A
- P/E Ratio
- BRNS N/A
- INTS N/A
- Revenue Growth
- BRNS 1766.46
- INTS N/A
- 52 Week Low
- BRNS $0.64
- INTS $0.88
- 52 Week High
- BRNS $2.60
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- BRNS 51.29
- INTS 21.48
- Support Level
- BRNS $0.68
- INTS $1.78
- Resistance Level
- BRNS $0.97
- INTS $1.94
- Average True Range (ATR)
- BRNS 0.08
- INTS 0.17
- MACD
- BRNS 0.02
- INTS -0.06
- Stochastic Oscillator
- BRNS 55.69
- INTS 3.75
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.